This presentation describes the new process by which the Centers for Medicare and Medicaid Services (CMS) will establish the prices the Agency pays for clinical diagnostic laboratory tests.  This revolutionary approach was
mandated by Congress in the clinical laboratory provisions contained within Section 216 of the Protecting Access to Medicare Act of 2014.  In his talk Dr. Klein will discuss this legislation, accompanying CMS regulations, and their
potential impacts on the laboratory industry